TCMs Not Paxlovid Gain Traction As Beijing On High Alert
But WHO Cautious On Findings
As Shanghai enters a second week of a city-wide lockdown with no signs of policy easing, officials are promoting the use of traditional Chinese medicines rather than Pfizer's recently approved Paxlovid.
You may also be interested in...
The role of a traditional Chinese medicine provided to the general public in China to fend off COVID-19 is controversial given limited evidence and even misleading, some say.
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.
Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.